Internal Medicine, Rheumatology · Staten Island, NY
NPI
1679568885
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1478 Victory Blvd
Staten Island, NY, 10301
Phone (718) 447-0055
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
125,399 services
Medicare patients, 2024
345
Average age 73
Drug cost, 2024
$6.2M
4,578 prescriptions
Company payments, 2025
$3,409
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark Goldstein was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 55,240 times for 15 patients. In total Mark Goldstein billed 125,399 services in 42 codes, and Medicare paid $1.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-02-28.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 55,240 | 15 | $3.63 | $200K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 7,251 | 13 | $33.75 | $245K |
| J0897 Injection, denosumab, 1 mg | Office | 6,000 | 61 | $20.65 | $124K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 3,703 | 47 | $0.10 | $372 |
| J9312 Injection, rituximab, 10 mg | Office | 3,200 | 11 | $61.29 | $196K |
| J7322 Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | Office | 1,392 | 14 | $13.45 | $19K |
| 99213 Office E&M - Established | Office | 604 | 282 | $71.87 | $43K |
| 96401 Chemotherapy Administration | Office | 382 | 76 | $63.33 | $24K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 248 | 40 | $0.52 | $128 |
| 96413 Chemotherapy Administration | Office | 248 | 41 | $121.10 | $30K |
| 96415 Chemotherapy Administration | Office | 115 | 14 | $25.62 | $2,946 |
| 20610 Joint Injection | Office | 107 | 43 | $67.11 | $7,180 |
| 99212 Office E&M - Established | Office | 72 | 48 | $44.20 | $3,182 |
| 99214 Office E&M - Established | Office | 44 | 39 | $104.94 | $4,618 |
| J1030 Injection, methylprednisolone acetate, 40 mg | Office | 27 | 18 | $3.89 | $105 |
By year: 2022 $1.3M for 102,253 services; 2023 $1.3M for 116,501 services; 2024 $1.3M for 125,399 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark Goldstein prescribed most often to Medicare patients was Prednisone, with 407 prescriptions and refills. In total Mark Goldstein wrote 4,578 Medicare prescriptions that cost $6.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 407 | 707 | 114 | $3,167 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 233 | 233 | 30 | $8,371 |
| Hydroxychloroquine Sulfate Generic | 201 | 500 | 53 | $9,024 |
| Methotrexate Methotrexate Sodium | 192 | 541 | 57 | $6,919 |
| Rinvoq Upadacitinib | 174 | 188 | 23 | $1.2M |
| Oxycodone Hcl Generic | 146 | 146 | 21 | $4,339 |
| Celecoxib Generic | 137 | 267 | 38 | $3,067 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 123 | 123 | 24 | $4,081 |
| Benlysta Belimumab | 105 | 105 | Under 11 | $510K |
| Gabapentin Generic | 104 | 188 | 23 | $1,220 |
| Allopurinol Generic | 97 | 282 | 28 | $1,798 |
| Alprazolam Generic | 95 | 95 | 14 | $602 |
| Pregabalin Generic | 91 | 97 | 17 | $805 |
| Duloxetine Hcl Generic | 84 | 194 | 32 | $2,660 |
| Hydromorphone Hcl Generic | 64 | 64 | Under 11 | $1,513 |
Brand drugs: - claims; generic drugs: 3,645 claims; opioid claims: 754.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark Goldstein $3,409 ($3,409 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $1,085.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 48 | $1,085 |
| UCB, Inc. UCB.BR | 27 | $460 |
| Amgen Inc. AMGN | 30 | $384 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $209 |
| Janssen Biotech, Inc. JNJ | 15 | $193 |
| Pfizer Inc. PFE | 10 | $158 |
| Genzyme Corporation SNY | 8 | $141 |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $135 |
| Aurinia Pharma U.S., Inc. AUPH | 4 | $99.96 |
| Radius Health, Inc. | 3 | $96.04 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.